BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 11357937)

  • 21. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
    Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity.
    Cochlovius B; Stassar MJ; Schreurs MW; Benner A; Adema GJ
    Immunol Lett; 2002 Feb; 80(2):89-96. PubMed ID: 11750039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination.
    Weth R; Christ O; Stevanovic S; Zöller M
    Cancer Gene Ther; 2001 Aug; 8(8):599-611. PubMed ID: 11571538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
    Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
    Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM; Odesa SK; Liau LM
    Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
    Rosenberg SA; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE
    Hum Gene Ther; 2003 May; 14(8):709-14. PubMed ID: 12804135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems.
    Kalariya M; Amiji MM
    Int J Pharm; 2013 Sep; 453(2):400-7. PubMed ID: 23702000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
    Irvine KR; Parkhurst MR; Shulman EP; Tupesis JP; Custer M; Touloukian CE; Robbins PF; Yafal AG; Greenhalgh P; Sutmuller RP; Offringa R; Rosenberg SA; Restifo NP
    Cancer Res; 1999 Jun; 59(11):2536-40. PubMed ID: 10363968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.
    Zhou WZ; Hoon DS; Huang SK; Fujii S; Hashimoto K; Morishita R; Kaneda Y
    Hum Gene Ther; 1999 Nov; 10(16):2719-24. PubMed ID: 10566900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.
    Tanaka M; Kaneda Y; Fujii S; Yamano T; Hashimoto K; Huang SK; Hoon DS
    Mol Ther; 2002 Mar; 5(3):291-9. PubMed ID: 11863419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.
    Astsaturov I; Petrella T; Bagriacik EU; de Benedette M; Uger R; Lumber G; Berinstein N; Elias I; Iscoe N; Hammond C; Hamilton P; Spaner DE
    Clin Cancer Res; 2003 Oct; 9(12):4347-55. PubMed ID: 14555505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.